# SMNDC1

## Overview
SMNDC1, or Survival Motor Neuron Domain Containing 1, is a gene that encodes a protein involved in RNA processing and splicing. The protein, also named SMNDC1, is characterized by its Tudor domain, which facilitates binding to methylated arginines, a critical step in spliceosome assembly. As a nuclear protein, SMNDC1 localizes to nuclear speckles, where it participates in the formation of membraneless organelles through liquid-liquid phase separation. This property is essential for its role in gene regulation and maintaining nuclear architecture. Functionally, SMNDC1 is integral to the spliceosome, contributing to the maturation of pre-mRNA and regulation of gene expression. Its involvement in cell proliferation and cancer progression, particularly through the modulation of exon retention and oncogenic signaling pathways, underscores its clinical significance. Additionally, SMNDC1's dysregulation is associated with neurological conditions, highlighting its broader impact on cellular and physiological processes (Zhang2022Activation; Enders2023Pharmacological; Guojun2024Phylogenetic).

## Structure
The SMNDC1 protein is characterized by its distinct molecular structure, which includes several key domains and features. The primary structure of SMNDC1 includes a sequence with conserved motifs, notably the Tudor domain, which spans residues 64-128. This domain is crucial for binding dimethylated arginines, facilitated by an aromatic cage composed of residues such as Trp83, Tyr90, Phe108, and Tyr111 (Enders2023Pharmacological; Guojun2024Phylogenetic). The secondary structure of SMNDC1 includes two N-terminal alpha-helices (residues 2-25 and 30-52) and a predicted long C-terminal alpha-helix, although the latter lacks experimental confirmation (Enders2023Pharmacological).

The tertiary structure is defined by the Tudor domain's aromatic cage, which mediates specific interactions through cation-π interactions (Enders2023Pharmacological). The protein's quaternary structure involves its localization to nuclear speckles, where it forms part of membraneless organelles through liquid-liquid phase separation, driven by its intrinsically disordered regions (IDRs) and RNA interactions (Enders2023Pharmacological).

SMNDC1 undergoes alternative splicing, resulting in multiple transcript isoforms, which contribute to its functional diversity (Guojun2024Phylogenetic). These structural features and modifications are essential for SMNDC1's role in spliceosome assembly and gene regulation.

## Function
The SMNDC1 gene encodes a protein that plays a crucial role in RNA processing and splicing within healthy human cells. This protein is involved in the formation of the spliceosome, a complex essential for the removal of introns from pre-mRNA, thereby facilitating proper mRNA maturation and gene expression regulation (Enders2023Pharmacological). SMNDC1 contains a Tudor domain, which is important for binding to methylated arginines on Sm-proteins, a key step in spliceosome assembly (Enders2023Pharmacological). 

SMNDC1 is primarily active in the nucleus, where it localizes to nuclear speckles, membraneless organelles involved in RNA processing. Its phase-separating properties, driven by its intrinsically disordered C-terminal region, are crucial for its function in gene regulation and maintaining nuclear architecture (Enders2023Pharmacological). The protein interacts with various splicing factors and pre-mRNA processing factors, highlighting its significant role in RNA splicing and processing (Guojun2024Phylogenetic).

In addition to its molecular functions, SMNDC1 is essential for cell proliferation and has been linked to worse survival outcomes in certain cancers, such as hepatocellular carcinoma, when overexpressed (Enders2023Pharmacological).

## Clinical Significance
The SMNDC1 gene is implicated in various cancers, with its overexpression linked to poor prognosis in several types, including breast, colon, rectal, pancreatic, and ovarian cancers. In these cancers, SMNDC1 promotes tumor growth and cell proliferation by enhancing the retention of specific exons during RNA splicing, such as exon 4 of MAPK3 (ERK1), which is crucial for kinase activity. This splicing alteration leads to increased ERK1 activation, promoting oncogenic signaling pathways and contributing to cancer progression (Zhang2022Activation).

In small-cell lung cancer, SMNDC1 is associated with acquired resistance to chemotherapy, with altered expression patterns correlating with patient survival outcomes. It is suggested to modulate resistance mechanisms through pathways like Notch and MYC (Yang2024Integrative).

SMNDC1 also plays a role in neurological conditions. The loss of a conserved poison exon in SMNDC1 leads to dysregulated splicing and expression of numerous transcripts, potentially causing neurological, physiological, or behavioral changes. This dysregulation is linked to growth restrictions and other developmental issues in model organisms (Belleville2024An).

## Interactions
SMNDC1 is involved in various protein interactions, particularly within the context of RNA processing and splicing. It interacts with proteins involved in small nuclear ribonucleoprotein (snRNP) complexes, splicing factors, and pre-mRNA processing factors in humans (Guojun2024Phylogenetic). SMNDC1 is also known to interact with SNRNP200, a component of the U5 snRNP, which plays a role in pre-mRNA splicing and is linked to diseases such as hereditary retinitis pigmentosa and acute myeloid leukemia (Guojun2024Phylogenetic).

The protein localizes to nuclear speckles, which are membraneless organelles formed by liquid-liquid phase separation (LLPS), and shows significant overlap with nuclear speckle markers like SC35 and SRRM2 (Enders2023Pharmacological). SMNDC1's interactions within nuclear speckles are mediated by its Tudor domain, which binds to dimethylarginine motifs on Sm proteins, crucial for spliceosome assembly (Enders2023Pharmacological; Wang2023Effectors). The C-terminal region of SMNDC1 is sufficient for droplet formation, indicating its role in phase separation and interaction with RNA (Enders2023Pharmacological).

Proximity labeling studies have revealed that SMNDC1 interacts with a wide range of proteins associated with mRNA processing, splicing, ribosome biogenesis, and rRNA processing, highlighting its extensive role in RNA metabolism (Enders2023Pharmacological).


## References


[1. (Wang2023Effectors) Yalong Wang and Mark T. Bedford. Effectors and effects of arginine methylation. Biochemical Society Transactions, 51(2):725–734, April 2023. URL: http://dx.doi.org/10.1042/bst20221147, doi:10.1042/bst20221147. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1042/bst20221147)

[2. (Belleville2024An) Andrea E. Belleville, James D. Thomas, Jackson Tonnies, Austin M. Gabel, Andrea Borrero Rossi, Priti Singh, Christine Queitsch, and Robert K. Bradley. An autoregulatory poison exon in smndc1 is conserved across kingdoms and influences organism growth. PLOS Genetics, 20(8):e1011363, August 2024. URL: http://dx.doi.org/10.1371/journal.pgen.1011363, doi:10.1371/journal.pgen.1011363. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1011363)

3. (Zhang2022Activation) Activation of ERK by altered RNA splicing in cancer. This article has 1 citations.

[4. (Yang2024Integrative) Fang Yang, Jinhua Fan, Runxiang Yang, and Yupeng Cun. Integrative analysis of blood transcriptome profiles in small-cell lung cancer patients for identification of novel chemotherapy resistance-related biomarkers. Frontiers in Immunology, June 2024. URL: http://dx.doi.org/10.3389/fimmu.2024.1338162, doi:10.3389/fimmu.2024.1338162. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2024.1338162)

[5. (Enders2023Pharmacological) Lennart Enders, Marton Siklos, Jan Borggräfe, Stefan Gaussmann, Anna Koren, Monika Malik, Tatjana Tomek, Michael Schuster, Jiří Reiniš, Elisa Hahn, Andrea Rukavina, Andreas Reicher, Tamara Casteels, Christoph Bock, Georg E. Winter, J. Thomas Hannich, Michael Sattler, and Stefan Kubicek. Pharmacological perturbation of the phase-separating protein smndc1. Nature Communications, August 2023. URL: http://dx.doi.org/10.1038/s41467-023-40124-0, doi:10.1038/s41467-023-40124-0. This article has 5 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-40124-0)

6. (Guojun2024Phylogenetic) Phylogenetic comparison and splice site conservation of the animal SMNDC1 gene family. This article has 0 citations.